I. Introduction
C. albicans is a fungus that normally lives as a commensally organism in humans. However, C. albicans is an opportunistic pathogen and one of the main agents of mucosal and systemic fungal infections (Brown et al., 2012) . It is a dimorphic fungus, which can be grown up in two main forms: 1. As a unicellular yeast 2. In fibrous form, which can be in the form of chains built from the merger of long cells, also known as the pseudohyphae or in the form of true hypha, which have the form of pipes with parallel page (Sudbery, 2011 ) . Filamentous forms prevail in the areas of primary epithelial infection. Morphological transformation may facilitate the introduction of C. albicans in the blood and therefore spreads in the form of a systemic infection . This morphological transformation is essential for the pathogenicity of C. albicans (Lo et al., 1997) . Although antimycotics used in clinical treatments are various, only a few classes of them are able to treat the mucosal or systemic infections caused by Candida spp. Figure 1 .1 shows the action mechanism of the main classes of antimycotics (Spampinato et al., 2013) . In the table below are presented the main classes of antimycotics, their way of action and key members of each class (Spampinato et al., 2013) .
Resistance of fungi has to do with their non sensitivity towards the antifungal agents proved through in vitro tests. Microbiological resistance can be primary (innate) or secondary (acquired). Resistance primary is seen in fungus which were not previously exposed to antimycotics, while subsidiary resistance is seen in strains that were previously exposed to antimycotics and is dependent on the change of gene expression (Kanafani et al., 2008) .
III. Results And Discussion
Towards ekonazol the strains of pathogenic C. albicans fungus resulted sensitive in 26% of analyzed cases, to nistatin and mikonazol in any case or 0%, to klotrimazol in 50% of cases, toward ketonazol in 34% of cases, toward amphotericin in 10 % of cases and to fluconazole in 74% of cases. So, we see that the C. albicans strains are more sensitive to fluconazole. Resistant to ekonazol these strains resulted in 66% of cases, to nistatin in 94% of cases, to mikonazol in all cases, to klotrimazol in 50% of cases, to ketonazol in 51% of cases, to amphotericin in 90% of cases and to fluconazole in 26% of cases. So, from these antimycogram results, is seen that from these 7 analyzed antimycotics, fluconazole has the highest action against the strains of the studied pathogenic fungus, C. albicans. While, the antimycotics on whose the strains of C. albicans are more resistant is mikonazol. These results are presented in Figure 1 .3.
Figure 1.2 Candida albicans antimycogram
This achieved result is confirmed also by literature, where in the study conducted by Jacqueline et al., 2010, was demonstrated that fluconazole is more useful against candidiasis in adults and children. The treatment through fluconazole is 90% effective and easily distributed throughout the body. In a study conducted in 2013 in the district of Elbasan, where it is analyzed also the antimycotic action of C. albicans strains, it showed that C. albicans is resistant to amphotericin and klotrimazol. While the antimycotic that fight it better, and against whom C. albicans is sensitive, resulted nistatin. C. albicans in our study is quite resistant toward nistatin and in no case resulted sensitive to it. This can be explained by the fact that the strains that we examined may have acquired resistance to this antimycotics. 
